Evgen Pharma PLC Grant of options (1541B)

TIDMEVG

RNS Number : 1541B

Evgen Pharma PLC

06 October 2020

Evgen Pharma plc

("Evgen" or the "Company")

Grant of Options

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 5 October 2020, certain employees and directors of the Company, including the following Persons Discharging Managerial Responsibility ("PDMR"), were granted nil cost options (the "Options") over a total of 4,387,547 ordinary shares in the Company exercisable, subject to the Options vesting, for a period of up to 10 years from the date of grant and governed by the rules of the Evgen Pharma plc Long Term Incentive Plan ("LTIP").

 
 PDMR               Position                   Options granted 
 Dr Huw Jones       Chief Executive Officer          2,978,004 
                   -------------------------  ---------------- 
 Richard Moulson    Chief Financial Officer            337,817 
                   -------------------------  ---------------- 
 

The Options will vest on the third anniversary of grant, and other than 1,489,002 Options awarded to Dr Jones on joining the Company and vesting if performance is satisfactory, are subject to performance based on a combination of total shareholder return ("TSR") measured against an index of comparator companies (70%), and performance against strategic corporate objectives over three years (30%). The minimum TSR from the grant date to the vesting date for any of the Options to vest is median performance against the index. Re-testing of this performance condition after the vesting date is not permitted.

Following this award there are 7,478,376 options in issue, representing 5.48% of the Company's issued share capital.

Enquiries:

 
 Evgen Pharma plc www.evgen.com                                          via Walbrook 
 Barry Clare, Chairman 
 Richard Moulson, CFO 
 
 finnCap www.finncap.com                                          [phone] 
 Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
 Alice Lane (ECM) 
 
 Walbrook PR                             [phone] or [e-mail] 
                                                           + 44 (0)7980 541 893 / +44 
 Paul McManus / Anna Dunphy                                           (0)7876 741 001 
 
 

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging managerial responsibilities/person closely associated 
 a)    Name                                                         Dr Huw Jones 
      -----------------------------------------------------------  --------------------------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Position/status                                              Chief Executive 
      -----------------------------------------------------------  --------------------------------------------------- 
 b)    Initial notification /Amendment                              Initial Notification 
      -----------------------------------------------------------  --------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, auction platform, auctioneer 
        or auction monitor 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Name                                                         Evgen Pharma Plc 
      -----------------------------------------------------------  --------------------------------------------------- 
 b)    Legal Entity Identifier                                      213800NO3E6TSTQO8K20 
      -----------------------------------------------------------  --------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; and (iv) each place where transactions have been 
        conducted 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Description of the financial instrument, type of             Options over ordinary shares of 0.25 pence each 
       instrument                                                    GB00BSWYN304 
 
       Identification code 
      -----------------------------------------------------------  --------------------------------------------------- 
 b)    Nature of the transaction                                    Grant of options 
      -----------------------------------------------------------  --------------------------------------------------- 
 c)    Currency                                                     GBP 
      -----------------------------------------------------------  --------------------------------------------------- 
 d)    Price(s) and volume(s)                                       Price(s)                   Volume(s) 
      -----------------------------------------------------------  -------------------------  ------------------------ 
   nil                                                                                         2,978,004 
  ------------------------------------------------------------------------------------------  ------------------------ 
 
 e)    Aggregated information 
        - Aggregated volume 
        - Price 
        - Aggregated total 
      --------------------------------------------------------------------------------------  ------------------------ 
 f)    Date of the transaction                                      2 October 2020 
      -----------------------------------------------------------  --------------------------------------------------- 
 g)    Place of the transaction                                     London Stock Exchange, AIM 
      -----------------------------------------------------------  --------------------------------------------------- 
 
 
 1     Details of the person discharging managerial responsibilities/person closely associated 
 a)    Name                                                         Richard Moulson 
      -----------------------------------------------------------  --------------------------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Position/status                                              Chief Financial Officer 
      -----------------------------------------------------------  --------------------------------------------------- 
 b)    Initial notification /Amendment                              Initial Notification 
      -----------------------------------------------------------  --------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, auction platform, auctioneer 
        or auction monitor 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Name                                                         Evgen Pharma plc 
      -----------------------------------------------------------  --------------------------------------------------- 
 b)    Legal Entity Identifier                                      213800NO3E6TSTQO8K20 
      -----------------------------------------------------------  --------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; and (iv) each place where transactions have been 
        conducted 
      ---------------------------------------------------------------------------------------------------------------- 
 a)    Description of the financial instrument, type of             Options over ordinary shares of 0.25 pence each 
       instrument 
                                                                     GB00BSWYN304 
       Identification code 
      -----------------------------------------------------------  --------------------------------------------------- 
 b)    Nature of the transaction                                    Grant of options 
      -----------------------------------------------------------  --------------------------------------------------- 
 c)    Currency                                                     GBP 
      -----------------------------------------------------------  --------------------------------------------------- 
 d)    Price(s) and volume(s)                                       Price(s)                   Volume(s) 
      -----------------------------------------------------------  -------------------------  ------------------------ 
   nil                                                                                         337,817 

  ------------------------------------------------------------------------------------------  ------------------------ 
 
 e)    Aggregated information 
        - Aggregated volume 
        - Price 
        - Aggregated total 
      --------------------------------------------------------------------------------------  ------------------------ 
 f)    Date of the transaction                                      2 October 2020 
      -----------------------------------------------------------  --------------------------------------------------- 
 g)    Place of the transaction                                     London Stock Exchange, AIM 
      -----------------------------------------------------------  --------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHKKPBBABDDAKK

(END) Dow Jones Newswires

October 06, 2020 02:00 ET (06:00 GMT)